Overview

Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and to Compare Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs Intravenous Standard of Care for the Treatment of IDA in an Inf

Status:
Unknown status

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.

Phase:

Phase 4

Details

Lead Sponsor:

American Regent, Inc.
Luitpold Pharmaceuticals

Treatments:

Dextrans
Ferric Compounds
Ferric gluconate
Ferric oxide, saccharated
Ferrosoferric Oxide
Hepcidins
Iron
Iron-Dextran Complex